Table 2.
Clinical drug trial with documentation on ILC available
| SETTING | TRIAL | DRUG | PATIENT POPULATION | % ILC INCLUDED | SUB-ANALYSIS | CENTRAL PATHOLOGY |
|---|---|---|---|---|---|---|
| Neoadjuvant | SAFIA59 | palbociclib (CDK4/6i) | HR+HER2− | 12.0 | No | No |
| IMpassion03133,a | atezolizumab (ICI) | TNBC | 2.0 | No | No | |
| GeparQuinto Lapatinib36 | lapatinib (TKI) | HR− HER2+ or HR+HER2+ if cN+ | 2.8 | Yes | No | |
| EPHOS B60 | lapatinib (TKI) | HER2+ | 4.0 | No | No | |
| GeparQuinto Everolimus35 | everolimus (mTORi) | HR− HER2+ or HR+HER2+ if cN+ | 10.8 | Yes | No | |
| Adjuvant | MAINtenance Afinitor61 | everolimus (mTORi) | HR+HER2− | 16.3 | No | No |
| Metastatic | PALOMA 223,b] | palbociclib (CDK4/6i) | HR+HER2− | 14.7 | No | No |
| PALOMA 424,b] | palbociclib (CDK4/6i) | HR+HER2− | 3.8 | No | No | |
| NCT0028165834,a] | lapatinib (TKI) | HER2+ | 4.7 | No | No | |
| DETECT III62 | lapatinib (TKI) | HER2− with HER2+ CTCs | 9.8 | No | No | |
| BELLE-238 | buparlisib (PI3Ki) | HR+HER2− | 13.0 | No | No | |
| INPRES63 | everolimus (mTORi) | HR+HER2− | 26.0 | Yes | No | |
| IMPROVE37 | everolimus (mTORi) | HR+HER2− | 24.7 | No | No |
cN clinical nodal status, CTCs circulating tumor cells, HR hormone receptor, TNBC triple negative breast cancer.
aExclusion of non-measurable disease.
bExclusion of non-measurable disease with the exception of bone-only disease.